The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis ; volume:19 ; number:1 ; day:10 ; month:6 ; year:2019 ; pages:1-10 ; date:12.2019
BMC cancer ; 19, Heft 1 (10.6.2019), 1-10, 12.2019
- Creator
-
Gu, Lihu
Khadaroo, Parikshit Asutosh
Su, Hui
Kong, Liya
Chen, Liangliang
Wang, Xianfa
Li, Xinlong
Zhu, Hepan
Zhong, Xin
Pan, Junhai
Chen, Manman
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-5785-z
- URN
-
urn:nbn:de:101:1-2019110421485914935482
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 1:18 PM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gu, Lihu
- Khadaroo, Parikshit Asutosh
- Su, Hui
- Kong, Liya
- Chen, Liangliang
- Wang, Xianfa
- Li, Xinlong
- Zhu, Hepan
- Zhong, Xin
- Pan, Junhai
- Chen, Manman
- SpringerLink (Online service)
Other Objects (12)
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody
The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Analysis of T cell responses during anti-PD-1 & anti-CTLA-4 dual blockade therapy and anti-PD-1 monotherapy in stage III/IV metastatic melanoma patients
Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy
The Evolving Landscape of Biomarkers for Anti-PD-1 or Anti-PD-L1 Therapy
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients
Combined anti‐PD‐1 and anti‐CTLA‐4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action
Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
Effects of Combination of Anti-CTLA-4 and Anti-PD-1 on Gastric Cancer Cells Proliferation, Apoptosis and Metastasis
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma
Isobutyric acid enhances the anti-tumour effect of anti-PD-1 antibody